Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma
Recruiting now · Phase 1/Phase 2
Conditions studied: Relapsed Neuroblastoma, Refractory Neuroblastoma, High-risk Neuroblastoma
In brief
This Phase 1/2 trial aims to determine the safety and feasibility of administration of autologous chimeric antigen receptor (CAR) T cells targeting the human Anaplastic Lymphoma Kinase (ALK) receptor in pediatric subjects with relapsed or refractory neuroblastoma (NB). The trial will be conducted in two phases: Phase 1 will determine the maximum tolerated dose (MTD) of autologous hALK.CAR T cells using a 3+3 dose escalation design. Phase 2 will be an expansion phase to determine rates of response to hALK.CAR T cells.
Key facts
- Study ID
- NCT06803875
- Run by
- Roberto Chiarle
- People needed
- 42
- Starts
- 2025-01-31
- Expected to finish
- 2029-12-31
- Last updated by the study team
- 2025-12-26
Who can join
Age: 1 and older, up to 29. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age ≥ 12 months and < 30 years at the time of consent. The first patient on each dose level will need to be age ≥ 6 years old
- Disease Status:
- Patients must have histologic verification of neuroblastoma at diagnosis or at relapse
- Patients must have high-risk neuroblastoma according to Children's Oncology Group (COG) risk classification at time of study enrollment
- Patients must have persistent/refractory or relapsed disease for which standard curative measures are no longer effective, as defined in the protocol
- Patients must have evaluable or measurable disease per the revised International Neuroblastoma Response Criteria (INRC)
- Adequate washout from prior treatment regimens
- Adequate organ function
- Adequate performance status defined as Lansky or Karnofsky performance score ≥50%
- Subjects of reproductive potential must agree to use acceptable birth control methods
- Signed informed consent
You may not qualify if…
- Pregnant or nursing (lactating) women
- Patients with uncontrolled active infection
- Patients who are concurrently receiving other investigational agents
- Patients who have received prior CART-cell or other gene-modified immune-effector cell therapy, are not eligible unless they are >8 weeks from time of infusion, have fully recovered from any associated toxicities and have documented lack of persistence of the product
- Patients with a known additional malignancy other than non-melanomatous skin cancer or carcinoma in situ, unless not requiring active treatment and stable or disease-free for at least 3 years
- Uncontrolled CNS metastasis
- CNS disorder such as cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or autoimmune disease with CNS involvement which may impair the ability to evaluate neurotoxicity
- History of severe hypersensitivity reaction to compounds used in the study
- HIV/HBV/HCV infection
- Patients receiving systemic steroid therapy (physiologic replacement, inhaled steroids and premedication for blood products are allowed)
- Primary immunodeficiency or history of systemic autoimmune disease requiring systemic immunosuppression/disease modifying agents within the last 2 years
- Uncontrolled intercurrent illness
- Inability to comply with the study requirements
Where it is running
- Boston Children's Hospital — Boston, Massachusetts, United States (enrolling)
- Dana-Farber Cancer Institute — Boston, Massachusetts, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.